Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-668 · 1 trial · 1 indication
Endoscopic improvement was defined as Mayo endoscopic subscore of 0 or 1. The endoscopic subscore is scored from 0 (Normal appearance mucosa) to 3 (severe disease, spontaneous bleeding, ulceration) with lower scores associated with better health outcomes.
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
| Arm | Type | Description |
|---|---|---|
| ABBV-668 | EXPERIMENTAL | Participants will receive ABBV-668 twice daily approximately at same time each day for 16 weeks. |
| Name | Type | Description |
|---|---|---|
| ABBV-668 | DRUG | Oral Capsule |
Inclusion Criteria: * Diagnosis of ulcerative colitis (UC) for at least 90 days prior to Baseline. Appropriate documentation of biopsy results consistent with the diagnosis of UC in the assessment of the Investigator, must be available. * Participant meets the following disease activity criteria: A...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 10 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Upadacitinib |
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Tulisokibart |
| Pfizer Inc. | PFE | 8 | PHASE3 | Etrasimod |
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Filgotinib |
| Abivax SA Sponsored ADR | ABVX | 2 | PHASE3 | ABX464 |
| Bristol-Myers Squibb Company | BMY | 5 | PHASE2 | Ozanimod |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| AnaptysBio, Inc. | ANAB | 1 | PHASE2 | Rosnilimab |
| Palatin Technologies, Inc. | PTN | 1 | PHASE2 | PL8177 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | GSK4528287 |
| Xencor, Inc. | XNCR | 1 | PHASE1 | XmAb942 |
| Sunshine Biopharma Incorporated | SBFM | 1 | PHASE2 | 627 |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
ABBV-668 is an investigational small molecule being developed for the treatment of moderate to severe ulcerative colitis, a form of inflammatory bowel disease. It is administered as an oral capsule and is currently in clinical development, though it is not yet approved by regulatory authorities.
ABBV-668 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with ulcerative colitis.
ABBV-668 is in Phase 2 clinical development. A Phase 2 study has been completed, which assessed adverse events and change in disease activity in adult participants with moderate to severe ulcerative colitis. The drug remains investigational and has not received FDA approval.
ABBV-668 has one completed Phase 2 clinical trial registered as NCT05570006. This study evaluated the drug in 30 adult participants with moderate to severe ulcerative colitis across the United States, Belgium, France, and Poland. The trial was not randomized, double-blind, or controlled.
ABBV-668 is administered as an oral capsule. In the completed Phase 2 study, adult participants with moderate to severe ulcerative colitis took the drug by mouth to assess its effects on disease activity and safety.